ELVTICKER
Elevance Health, Inc.
Congress has disclosed 24 buys and 20 sells of ELV (Elevance Health, Inc.) in official financial disclosures, each linked to its original filing. A transparency record — not investment advice.
Activity Congressional Activity
24
Buy
20
Sell
+4
Net
15
Active politicians
Round-trip watch Still on the books
Members who disclosed buying ELV and have not disclosed selling, versus their own entry (the most recent disclosed buy). "Open" means no disclosed sale — never "still holds" — and the % is unrealised, on paper. Not investment advice.
| Member | Entry (last buy) | Entry price | Now | vs entry | Status |
|---|---|---|---|---|---|
| Jared Moskowitz | 2024-11-08 | $406.94 | $420.07 | +3.2% | ↩ near entry |
| Valerie Hoyle | 2024-10-29 | $395.34 | $420.07 | +6.3% | ↩ near entry |
| Gilbert Cisneros | 2025-08-05 | $269.55 | $420.07 | +55.8% | in profit |
| Alan Armstrong | 2026-03-27 | $283.99 | $420.07 | +47.9% | in profit |
| Rohit Khanna | 2026-02-24 | $322.41 | $420.07 | +30.3% | in profit |
| Lisa McClain | 2025-07-10 | $337.28 | $420.07 | +24.5% | in profit |
Price as of 2026-10-30. Counted open while disclosed buys outnumber disclosed sells; tracks the price, not exact position size (amounts are ranges).
Price & congressional trades
Buy
Sell
Fundamentals · FY2026 Valuation
Standard valuation multiples from SEC-reported GAAP financials (trailing twelve months), each compared to the median for Insurance. We use reported GAAP, not forward or adjusted earnings, so our figures can sit higher than sites that do — especially for companies with falling profit. Relative context — not a target price or investment advice.
P/E
17.66
▲ pricier than
Insurance (median 13.5)
how it's calculated
P/E = price ÷ earnings per share
$420.07 ÷ $23.79 = 17.66
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.
P/B
2.03
≈ in line with
Insurance (median 2.0)
how it's calculated
P/B = price ÷ book value per share
$420.07 ÷ $206.80 = 2.03
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.
EV/EBITDA
15.94
▲ pricier than
Insurance (median 13.6)
how it's calculated
EV/EBITDA = (market cap + net debt) ÷ EBITDA
($90.8B + $20.4B net debt) ÷ $7.0B = $111.2B ÷ $7.0B = 15.94
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.
Legislation Related Legislation
Recent bills in this stock's sector (Insurance). Sector-level context from Congress.gov — a bill names a policy area, not this company specifically.
| Bill | Title | Policy area | Latest action |
|---|---|---|---|
| HR 10820 | Epstein Wall Street Records Act of 2026 | Finance and Financial Sector | 2026-10-15 |
| HR 10821 | To amend the Federal Deposit Insurance Act to make changes to the Standard Maximum Deposit Insurance Amount, and for other purposes. | Finance and Financial Sector | 2026-10-15 |
| S 4395 | Terrorism Risk Insurance Program Reauthorization Act of 2026 | Finance and Financial Sector | 2026-10-05 |
| S 1564 | Floodplain Enhancement and Recovery Act | Finance and Financial Sector | 2026-10-05 |
| S 5644 | A bill to amend title 31, United States Code, to exempt transactions with respect to cash reward payments by crime stopper organizations from certain currency transaction reports. | Finance and Financial Sector | 2026-09-30 |
44 trades Recent Congressional Trades
Two things to watch per trade: the disclosure lag (how many days passed before the trade was made public) and the price move in that window (how the stock moved during those non-public days). A sell followed by a price drop, or a buy followed by a rise, means well-timed trading — visible here in the open. Note: the Score measures how notable a trade is, not whether it made money — the price move is shown for context and isn't part of it.
| Politician | Chamber | Type | Owner | Date | Disclosure lag | Price move in that window | Amount | Score | Source |
|---|---|---|---|---|---|---|---|---|---|
| Alan Armstrong | Senate | BUY ◆ insider convergence · moderate | Self | 2026-03-27 | 116 days | +37.9% | $1K–$15K | 82.9 | ↗ eFD |
| Rohit Khanna | House | BUY OCR ◆ insider convergence · moderate | Child | 2026-02-24 | 8 days | -10.9% | $15K–$50K | 24.8 | ↗ filing |
| Michael McCaul | House | SELL OCR | Spouse | 2025-10-27 | 9 days | -7.1% | $15K–$50K | 48.4 | ↗ filing |
| Rohit Khanna | House | BUY OCR ◆ insider convergence · moderate | Child | 2025-09-29 | 3 days | +6.4% | $1K–$15K | 7.3 | ↗ filing |
| Lisa McClain | House | SELL ◆ insider divergence · strong | Spouse · Charles Schwab Brokerage Account 924 | 2025-08-13 | 19 days | +8.2% | $1K–$15K 0.1% of NW |
67.1 | ↗ filing |
| Gilbert Cisneros | House | BUY ◆ insider convergence · strong | Self · 150 Main Street Trust > Bank of America | 2025-08-05 | 34 days | +11.5% | $1K–$15K 0.1% of NW |
22.3 | ↗ filing |
| Lisa McClain | House | BUY ◆ insider convergence · strong | Spouse · Charles Schwab Brokerage Account 924 | 2025-07-10 | 34 days | -14.9% | $1K–$15K 0.1% of NW |
89.5 | ↗ filing |
| Lisa McClain | House | BUY ◆ insider convergence · strong | Spouse · Charles Schwab Brokerage Account 924 | 2025-06-24 | 50 days | -21.8% | $1K–$15K 0.1% of NW |
97.4 | ↗ filing |
| Gilbert Cisneros | House | SELL ◆ insider divergence · strong | Self · 150 Main Street Trust > Bank of America | 2025-05-30 | 5 days | -1.0% | $1K–$15K 0.1% of NW |
50.8 | ↗ filing |
| Rob Bresnahan | House | SELL ◆ insider convergence | Self · JP Morgan Brokerage Account | 2025-05-15 | 0 days | 0.0% | $15K–$50K 0.9% of NW |
64.1 | ↗ filing |
| Jefferson Shreve | House | SELL ◆ insider convergence | Self · CRT - Standard Unit Trust | 2025-05-12 | 3 days | -6.4% | $15K–$50K <0.1% of NW |
89.4 | ↗ filing |
| Gilbert Cisneros | House | BUY ◆ insider divergence · moderate | Self · 150 Main Street Trust > Bank of America | 2025-04-29 | 6 days | +0.6% | $1K–$15K 0.1% of NW |
63.0 | ↗ filing |
| Dan Newhouse | House | SELL ◆ insider convergence · moderate | Spouse · Edward Jones IRA | 2025-04-11 | 20 days | -7.2% | $1K–$15K <0.1% of NW |
26.9 | ↗ filing |
| Rohit Khanna | House | BUY OCR ◆ insider divergence · moderate | Child | 2025-03-12 | 26 days | +2.9% | $1K–$15K | 8.6 | ↗ filing |
| Jared Moskowitz | House | SELL ◆ insider convergence · moderate | Child · Morgan Stanley Active Assets (5) | 2025-03-10 | 21 days | +6.2% | $1K–$15K 0.3% of NW |
1.0 | ↗ filing |
| Jared Moskowitz | House | SELL ◆ insider convergence · moderate | Child · Morgan Stanley Active Assets (6) | 2025-03-10 | 21 days | +6.2% | $1K–$15K 0.3% of NW |
1.0 | ↗ filing |
| Jared Moskowitz | House | SELL ◆ insider convergence · moderate | Self · Morgan Stanley Active Assets (1) | 2025-03-10 | 21 days | +6.2% | $1K–$15K 0.3% of NW |
1.0 | ↗ filing |
| Rob Bresnahan | House | SELL ◆ insider convergence | Joint · Joint Ownership LPL Account | 2025-01-13 | 0 days | 0.0% | $1K–$15K 0.2% of NW |
67.0 | ↗ filing |
| Michael McCaul | House | SELL OCR ◆ insider convergence | Spouse | 2025-01-09 | 27 days | +4.9% | $15K–$50K | 63.1 | ↗ filing |
| Rohit Khanna | House | BUY OCR | Child | 2024-12-18 | 20 days | +4.0% | $1K–$15K | 10.6 | ↗ filing |
| Jared Moskowitz | House | BUY ◆ insider divergence | Child · Morgan Stanley Active Assets (5) | 2024-11-08 | 22 days | -3.7% | $1K–$15K 0.3% of NW |
11.6 | ↗ filing |
| Valerie Hoyle | House | BUY ◆ insider divergence | Spouse · Fidelity Rollover IRA | 2024-10-29 | 317 days | -21.9% | $1K–$15K 0.8% of NW |
69.5 | ↗ filing |
| John James | House | SELL ◆ insider convergence | Self · John A. James Children’s Trust | 2024-09-04 | 1 days | -0.5% | $1K–$15K <0.1% of NW |
20.0 | ↗ filing |
| Michael McCaul | House | SELL OCR ◆ insider convergence | Spouse | 2024-08-26 | 10 days | -0.0% | $50K–$100K | 96.1 | ↗ filing |
| Jared Moskowitz | House | BUY ◆ insider divergence | Child · Morgan Stanley Active Assets (6) | 2024-07-05 | 26 days | — | $1K–$15K 0.3% of NW |
6.1 | ↗ filing |
| Jared Moskowitz | House | BUY ◆ insider divergence | Child · Morgan Stanley Active Assets (5) | 2024-07-01 | 30 days | — | $1K–$15K 0.3% of NW |
9.4 | ↗ filing |
| Dan Newhouse | House | BUY ◆ insider divergence · moderate | Spouse · Edward Jones IRA | 2024-04-10 | 0 days | — | $1K–$15K <0.1% of NW |
62.7 | ↗ filing |
| Jared Moskowitz | House | BUY ◆ insider divergence | Self · Morgan Stanley Active Assets (1) | 2024-02-13 | 181 days | — | $1K–$15K 0.3% of NW |
14.3 | ↗ filing |
| Jared Moskowitz | House | BUY ◆ insider divergence · moderate | Child · Morgan Stanley Active Assets (5) | 2024-02-01 | 28 days | — | $1K–$15K 0.3% of NW |
64.6 | ↗ filing |
| Jared Moskowitz | House | BUY ◆ insider divergence · moderate | Self · Morgan Stanley Active Assets (1) | 2024-02-01 | 193 days | — | $1K–$15K 0.3% of NW |
64.6 | ↗ filing |
| Rohit Khanna | House | BUY OCR ◆ insider divergence | Child | 2023-12-05 | 30 days | — | $1K–$15K | 26.5 | ↗ filing |
| John Curtis | House | SELL ◆ insider convergence | Joint · Northwestern Mutual - Joint | 2023-12-04 | 0 days | — | $1K–$15K | 22.3 | ↗ filing |
| John James | House | BUY ◆ insider divergence | Self · John A. James Children’s Trust | 2023-11-16 | 271 days | — | $1K–$15K <0.1% of NW |
52.4 | ↗ filing |
| John James | House | BUY ◆ insider divergence | Self · John A. James Children’s Trust | 2023-11-10 | 277 days | — | $1K–$15K <0.1% of NW |
86.8 | ↗ filing |
| Greg Stanton | House | SELL ◆ insider convergence | Spouse | 2023-10-24 | 2 days | — | $1K–$15K 0.5% of NW |
40.4 | ↗ filing |
| Greg Stanton | House | BUY ◆ insider divergence | Spouse | 2023-09-26 | 25 days | — | $1K–$15K 0.5% of NW |
75.9 | ↗ filing |
| Rick Larsen | House | SELL ◆ insider convergence | Self · Richard R Larsen IRA > Ameriprise SPS Managed Account | 2023-07-05 | 8 days | — | $1K–$15K 0.7% of NW |
40.4 | ↗ filing |
| John Curtis | House | BUY ◆ insider divergence | Joint · Northwestern Mutual - Joint | 2023-04-26 | 6 days | — | $1K–$15K | 40.4 | ↗ filing |
| Rohit Khanna | House | BUY OCR ◆ insider divergence | Child | 2023-03-24 | 10 days | — | $1K–$15K | 22.3 | ↗ filing |
| Rohit Khanna | House | SELL OCR ◆ insider convergence | Child | 2023-02-14 | 15 days | — | $1K–$15K | 40.4 | ↗ filing |
| Rohit Khanna | House | SELL OCR ◆ insider convergence | Child | 2023-01-11 | 22 days | — | $1K–$15K | 93.1 | ↗ filing |
| Rick Larsen | House | BUY | Self · Richard R Larsen IRA > Ameriprise SPS Managed Account | 2023-01-06 | 132 days | — | $1K–$15K 0.7% of NW |
75.9 | ↗ filing |
| Robert Wittman | House | SELL | Self · Morgan Stanley | 2023-01-03 | 2 days | — | $1K–$15K 0.2% of NW |
93.1 | ↗ filing |
| John Curtis | House | SELL | Joint · Northwestern Mutual - Joint | 2022-12-20 | 14 days | — | $1K–$15K | 93.1 | ↗ filing |
Corporate insiders · SEC Form 4 Insider Activity
What the company's own officers and directors did in ELV — open-market purchases and sales from SEC Form 4 filings (option exercises, grants and tax withholding are excluded). This is context for the congressional activity above, never a buy/sell signal, and the two datasets are kept separate on purpose. Does convergence mean anything? →
21
Congress trades with insider convergence
18
…with insider divergence
59
Insider open-market trades
Of the congressional trades in ELV, 21 coincided with corporate insiders moving the same way within 60 days, and 18 with insiders moving the opposite way. This is co-occurrence only — whether it carries any edge is tested honestly on the convergence page.
| Date | Insider | Role | Type | Size | Source |
|---|---|---|---|---|---|
| 2026-10-22 | Kaye Mark | C-suite | SELL | $174K | ↗ EDGAR |
| 2026-10-22 | Kaye Mark | C-suite | SELL | $140K | ↗ EDGAR |
| 2026-10-22 | Kaye Mark | C-suite | SELL | $724K | ↗ EDGAR |
| 2026-10-22 | Kaye Mark | C-suite | SELL | $245K | ↗ EDGAR |
| 2026-10-22 | Kaye Mark | C-suite | SELL | $105K | ↗ EDGAR |
| 2026-10-22 | Kaye Mark | C-suite | SELL | $510K | ↗ EDGAR |
| 2026-10-22 | Kaye Mark | C-suite | SELL | $758K | ↗ EDGAR |
| 2026-10-22 | Kaye Mark | C-suite | SELL | $1.0M | ↗ EDGAR |
| 2026-10-22 | Kaye Mark | C-suite | SELL | $212K | ↗ EDGAR |
| 2026-10-22 | Kaye Mark | C-suite | SELL | $195K | ↗ EDGAR |
| 2026-10-22 | Kaye Mark | C-suite | SELL | $71K | ↗ EDGAR |
| 2026-10-22 | Kaye Mark | C-suite | SELL | $369K | ↗ EDGAR |
| 2026-10-22 | Kaye Mark | C-suite | SELL | $122K | ↗ EDGAR |
| 2026-07-17 | PERU RAMIRO G | Director | BUY | $366K | ↗ EDGAR |
| 2026-07-17 | BOUDREAUX GAIL | C-suite | BUY | $249K | ↗ EDGAR |
| 2026-07-17 | BOUDREAUX GAIL | C-suite | BUY | $753K | ↗ EDGAR |
| 2026-06-12 | Penczek Ronald W | Other | SELL | $149K | ↗ EDGAR |
| 2026-06-11 | Dixon Robert L JR | Director | SELL | $61K | ↗ EDGAR |
| 2026-05-19 | Penczek Ronald W | Other | SELL | $617K | ↗ EDGAR |
| 2026-03-12 | SCHULMAN AMY W | Director | SELL | $7K | ↗ EDGAR |
| 2026-03-06 | Kendrick Charles Morgan JR | C-suite | SELL | $911K | ↗ EDGAR |
| 2026-03-05 | COLLIS STEVEN H | Director | BUY | $870K | ↗ EDGAR |
| 2025-08-19 | DeVore Susan D. | Director | BUY | $375K | ↗ EDGAR |
| 2025-07-18 | BOUDREAUX GAIL | C-suite | BUY | $668K | ↗ EDGAR |
| 2025-07-18 | BOUDREAUX GAIL | C-suite | BUY | $1.5M | ↗ EDGAR |
Combined timeline — Congress & insiders
Both sets of trades on one timeline, newest first, so you can see when they lined up. Congress vs ◆ insider.
| Date | Who | Type | Size | |
|---|---|---|---|---|
| ◆ insider | 2026-10-22 | Kaye Mark C-suite | SELL | $174K |
| ◆ insider | 2026-10-22 | Kaye Mark C-suite | SELL | $140K |
| ◆ insider | 2026-10-22 | Kaye Mark C-suite | SELL | $724K |
| ◆ insider | 2026-10-22 | Kaye Mark C-suite | SELL | $245K |
| ◆ insider | 2026-10-22 | Kaye Mark C-suite | SELL | $105K |
| ◆ insider | 2026-10-22 | Kaye Mark C-suite | SELL | $510K |
| ◆ insider | 2026-10-22 | Kaye Mark C-suite | SELL | $758K |
| ◆ insider | 2026-10-22 | Kaye Mark C-suite | SELL | $1.0M |
| ◆ insider | 2026-10-22 | Kaye Mark C-suite | SELL | $212K |
| ◆ insider | 2026-10-22 | Kaye Mark C-suite | SELL | $195K |
| ◆ insider | 2026-10-22 | Kaye Mark C-suite | SELL | $71K |
| ◆ insider | 2026-10-22 | Kaye Mark C-suite | SELL | $369K |
| ◆ insider | 2026-10-22 | Kaye Mark C-suite | SELL | $122K |
| ◆ insider | 2026-07-17 | PERU RAMIRO G Director | BUY | $366K |
| ◆ insider | 2026-07-17 | BOUDREAUX GAIL C-suite | BUY | $249K |
| ◆ insider | 2026-07-17 | BOUDREAUX GAIL C-suite | BUY | $753K |
| ◆ insider | 2026-06-12 | Penczek Ronald W Other | SELL | $149K |
| ◆ insider | 2026-06-11 | Dixon Robert L JR Director | SELL | $61K |
| ◆ insider | 2026-05-19 | Penczek Ronald W Other | SELL | $617K |
| Congress | 2026-03-27 | Alan Armstrong | BUY | $1K–$15K |
| ◆ insider | 2026-03-12 | SCHULMAN AMY W Director | SELL | $7K |
| ◆ insider | 2026-03-06 | Kendrick Charles Morgan JR C-suite | SELL | $911K |
| ◆ insider | 2026-03-05 | COLLIS STEVEN H Director | BUY | $870K |
| Congress | 2026-02-24 | Rohit Khanna | BUY | $15K–$50K |
FAQ Common questions
How much has Congress traded ELV?
24 disclosed buys and 20 sells of ELV (Elevance Health, Inc.) appear in official congressional financial disclosures.
Is it legal for members of Congress to trade ELV?
Members of Congress may trade stocks but must disclose it under the STOCK Act. QuantCapitol tracks those public disclosures for transparency — nothing here is an accusation of wrongdoing or investment advice.
Where does this data come from?
Official US House Clerk and Senate electronic financial disclosures. Every trade links back to its original filing so you can verify it yourself.